Adjunctive therapies in type 1 (insulin plus pramlintide, or SGLT2 inhibitors), and combination therapies in type 2 diabetes (metformin plus SGLT2 inhibitors or glucagon-like peptide analogs) may be compared with traditional treatments thanks to the use of conventional glucose devices and the introduction of new devices for CGM 183, 184. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.